POTS Adrenergic Ab (CIHR Aims #1&2)

• Status: Recruiting
• Trial end date: 2023-12-01

Summary

Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.

Details

• Lead Sponsor: University of Calgary
• Treatments: Adrenergic Agents; Isoproterenol; Oxymetazoline; Phenylephrine